Trial Profile

STI571 Prospective International RandomIsed Trial 2: A phase III, prospective randomised comparison of imatinib (STI571, Glivec/ Gleevec) 400 mg daily versus dasatinib (Sprycel) 100 mg daily in patients with newly-diagnosed chronic phase chronic myeloid leukaemia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Dec 2018 Primary endpoint (Event-free survival) has not been met, as per results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
04 Dec 2018 Final results assessing survival rates presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
01 Jul 2016 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com